HFSA 2006 Comprehensive Heart Failure Practice Guideline.
about
Loss-of-function DNA sequence variant in the CLCNKA chloride channel implicates the cardio-renal axis in interindividual heart failure risk variationRole of the Lebanese family caregivers in cardiac self-care: a collective approachManagement of end-stage heart failure: a perspective on the Arab Gulf statesPeak myocardial acceleration during isovolumic relaxation time predicts the occurrence of rehospitalization in chronic heart failure: data from the Daunia heart failure registry.Survival and cardioprotective benefits of long-term blueberry enriched diet in dilated cardiomyopathy following myocardial infarction in rats.Additional Prognostic Value of EAS index in predicting the occurrence of rehospitalizations in chronic heart failure: data from the Daunia Heart Failure Registry.Patient expectations from implantable defibrillators to prevent death in heart failure.Development, psychometric testing, and revision of the Atlanta Heart Failure Knowledge Test.Short-term mortality and cost associated with cardiac device implantation in patients hospitalized with heart failure.Beta-blockers Associated with a Mortality Benefit in Patients with Systolic Dysfunction and Elevated Serum Bilirubin.Adherence to the low-sodium diet plays a role in the interaction between depressive symptoms and prognosis in patients with heart failureCurrent treatment options for early management in acute decompensated heart failure.Pharmacodynamics of a novel designer natriuretic peptide, CD-NP, in a first-in-human clinical trial in healthy subjects.Dietary sodium restriction below 2 g per day predicted shorter event-free survival in patients with mild heart failureLink between decisions regarding resuscitation and preferences for quality over length of life with heart failure.Biomarker changes during acute heart failure treatment.Clinical Effectiveness of Hydralazine-Isosorbide Dinitrate Therapy in Patients With Heart Failure and Reduced Ejection Fraction: Findings From the Get With The Guidelines-Heart Failure RegistryMechanisms of disease: detrimental adrenergic signaling in acute decompensated heart failure.Devices in heart failure: potential methods for device-based monitoring of congestive heart failure.Discordance between patient-predicted and model-predicted life expectancy among ambulatory patients with heart failure.Early pharmacological treatment of acute heart failure syndromes: a systematic review of clinical trials.Comparison of medication practices in patients with heart failure and preserved versus those with reduced ejection fraction (from the Cardiovascular Research Network [CVRN]).Quality of care for decompensated heart failure: comparable performance between academic hospitalists and non-hospitalistsA practical use of theory to study adherence.Management strategies for stage-D patients with acute heart failurePrecipitant in acute heart failure in a multiethnic Asian urban cohort study.Relations of circulating resistin and adiponectin and cardiac structure and function: the Framingham Offspring Study.Critical elements of clinical follow-up after hospital discharge for heart failure: insights from the EVEREST trialBaseline differences in the HF-ACTION trial by sex.Renin-angiotensin-aldosterone system (RAAS) pharmacogenomics: implications in heart failure management.Family caregiver outcomes in heart failureTreating volume overload in acutely decompensated heart failure: established and novel therapeutic approachesBody mass index and vigorous physical activity and the risk of heart failure among menThe CopenHeartSF trial--comprehensive sexual rehabilitation programme for male patients with implantable cardioverter defibrillator or ischaemic heart disease and impaired sexual function: protocol of a randomised clinical trial.Electronically monitored medication adherence predicts hospitalization in heart failure patients.Therapeutic efficacy of a combination of a beta1-adrenoreceptor (AR) blocker and beta2-AR agonist in a rat model of postmyocardial infarction dilated heart failure exceeds that of a beta1-AR blocker plus angiotensin-converting enzyme inhibitor.Society of Chest Pain Centers recommendations for the evaluation and management of the observation stay acute heart failure patient-parts 1-6.Improvements in signs and symptoms during hospitalization for acute heart failure follow different patterns and depend on the measurement scales used: an international, prospective registry to evaluate the evolution of measures of disease severity iHeart failure with preserved ejection fraction in the elderly: scope of the problem.A program of professional accreditation of hospital wards by the Italian Society of Internal Medicine (SIMI): self- versus peer-evaluation.
P2860
Q24625036-F39E6179-7BC7-4BD7-823D-6754FB7569B2Q28386667-805832C3-F7CC-4CE8-B9E5-FBB5B20638E6Q28751716-821F5B5C-EF26-471A-B669-79940C59CFDEQ30678040-06B2C324-DDD4-40B1-AD66-F9F0CCC3BB34Q30914034-43AE08A8-4155-44C0-B5F1-8CD478D35D0AQ30985982-0656206E-F24B-4401-A510-7D17BE295226Q33158361-0C6484EF-E695-423E-A279-93E583D583B4Q33685996-14952E15-DD40-476B-8CD3-B37828BB85C7Q33735354-F1C56226-4DA0-40AC-AD52-97CA9C177786Q34211025-37037C74-9D8F-4BA6-A7F5-44A8C796B380Q34596943-46FD320A-364E-4E5C-9035-84CB0CFBB469Q34796529-2E7728E2-9947-471E-878B-8C926485E6E6Q35086433-F7B1D218-3E6C-4236-A1CE-F0D614228FC7Q35372760-60A9E3DC-F260-4497-959B-797733D431F6Q35746978-578FB639-412D-4B6A-B831-0BD684C5BAD7Q35854988-04ABB3F5-F6D8-4E7E-8400-5C0225795080Q36584895-5F619B43-6E95-4664-9777-7EBC937713D0Q36699897-322679BE-0ECD-444E-A52F-DD81837DA4DFQ36732200-D034B959-D855-45F1-B7C6-DFA516576C8FQ36758142-0337B4A6-3DE3-44EE-B515-4C87C6CC2C7BQ36799331-FE7056F7-D8EE-43C9-BBB5-6A5F526A28A2Q36807898-B38A4510-76C5-4A15-9D95-38142AB9445AQ36841064-F0A653EE-CA4C-4D19-9D6A-A80EA8956BC3Q36929382-53421406-5C4C-40C0-B4F9-76351E050949Q36980470-733785D2-D491-410A-AAFE-166341B979CEQ36982576-D9558368-0CEA-495A-88C3-62A7901ED9D3Q37026291-E47AE45B-74DA-40E9-869F-3E0604687E43Q37066197-F448248B-A273-4829-B083-EF3209D19E2DQ37109299-89CE01DF-C596-4EE3-A269-2E15DE6799B1Q37113826-3F938DC6-3F07-42EA-A38C-8A5F647FAFEFQ37118250-68E903F9-4F85-4BF1-80EA-B0E995C33891Q37140940-E9CEF752-A52E-4E59-B0E7-4797586A9698Q37307461-92F048D0-797D-4B19-87B4-2C7893A83D60Q37352860-0D5FE0F4-B697-4CC4-BA93-3C2ACA7D8D16Q37391005-95588DB9-3EFD-4EE9-B766-7A20F59C9F1DQ37397232-704D4E26-BF30-4DBB-936A-76FB885E84BBQ37461040-98941DF1-4AC9-4EB1-A817-14E0C650DFF9Q37653092-198FEAB3-BE41-42B4-8EC2-9215AFD148DBQ37912065-7B95FD7A-1D3C-4DD7-92BC-D373246255CAQ37915385-09019C48-D71F-4A60-B782-DA8B4983B5AA
P2860
HFSA 2006 Comprehensive Heart Failure Practice Guideline.
description
2006 nî lūn-bûn
@nan
2006 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
HFSA 2006 Comprehensive Heart Failure Practice Guideline.
@ast
HFSA 2006 Comprehensive Heart Failure Practice Guideline.
@en
HFSA 2006 Comprehensive Heart Failure Practice Guideline.
@nl
type
label
HFSA 2006 Comprehensive Heart Failure Practice Guideline.
@ast
HFSA 2006 Comprehensive Heart Failure Practice Guideline.
@en
HFSA 2006 Comprehensive Heart Failure Practice Guideline.
@nl
prefLabel
HFSA 2006 Comprehensive Heart Failure Practice Guideline.
@ast
HFSA 2006 Comprehensive Heart Failure Practice Guideline.
@en
HFSA 2006 Comprehensive Heart Failure Practice Guideline.
@nl
P1476
HFSA 2006 Comprehensive Heart Failure Practice Guideline.
@en
P2093
Heart Failure Society Of America
P356
10.1016/J.CARDFAIL.2005.11.005
P577
2006-02-01T00:00:00Z